Ferring Pharmaceuticals, Inc. has edged ahead in the race to bring the first microbiome-based drug to market in the United States, with its product REBYOTA receiving the thumbs up from the FDA’s Vaccines and Related […]
Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential […]
The Microbiome Signature Project arranges a Pitch Day on 27 September in Malmö, Sweden as the final event of the three-year-long project. It is a unique event to showcase startups in Medicon Valley within the […]
Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces the registration of its phagogram as an in vitro diagnostic test (“Phagogram 1.5”) […]
Key studies in the last decade have shown that the gut microbiome, the collection of hundreds of bacterial species that live in the human digestive system, influences neural development, response to cancer immunotherapies, and other […]
Gensaic, a company that seeks to reimagine gene therapy, announced today that it has entered into a strategic collaboration agreement with Ovid Therapeutics. Under the terms of the collaboration, Gensaic will exclusively develop phage-derived gene […]